NEW YORK (GenomeWeb News) – The Scottish company CXR Biosciences said today it will work with the University of Dundee and Wyeth Pharmaceuticals in a £3 million ($6.2 million) collaboration to seek protein biomarkers that indicate the toxic effects of certain drugs.
 
CXR Bio said the three-year project is co-funded by the Technology Strategy Board and will be conducted in part by Wyeth scientists and by core lab staff at the Translational Medicine Research Center in Dundee.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.